Since the early 1990s, screening for prostate cancer is based on digital rectal examination and a blood assay, called PSA. But U.S. researchers show that good results do not eliminate the risk of tumor. The annual evolution of the SAP would prove a much better indicator.
Screening for prostate cancer depends on the dosage in the blood of a specific marker of a dysfunction of the prostate (called PSA specific antigen). But for several years, this review is in jeopardy …
A low dosage does not increase the risk of cancer
ProstateQuelle cancer is the actual reliability of the PSA assay? To provide a definitive answer, the team of Ian Thompson has enrolled nearly 10 000 men over 55 years1. For seven years on average, each of them has suffered an annual PSA assay, digital rectal examination and biopsy. Of normal rectal touch (no perception of abnormal area on the gland) and dosages PSA below 4 ng / ml are usually associated with a low risk of cancer. Among men participating in the study, 2 950 fell into this category.
But after a biopsy, no less than 449 (15.2%) of them turn out to be cancer patients, 67 of which were sophisticated. [click to continue…]
{ 1 comment }
Prostate cancer is the most common cancers in men over 60 years. It is possible to detect prostate cancer early in its evolution. Strictly speaking, we can not prevent the onset of prostate cancer, but you can detect when its size is still very small in a regular review. This is the same as for women who are advised screening for cancer of the breast or cervix.